Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy

Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy - neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate for high-risk prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027581

Enrollment

100

Registered

2017-05-31

Start date

2017-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

A principal investigator or subinvestigators make a decision of an agent for neodjuvant hormone therapy. Participants are treated with neoadjuvant hormone therapy for 6 months before intensity modulat

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)PSA>20 or Gleason scores>=8 or Tumor stage T2c~T3(high risk prsotate cancer) 2)patients without history of hormone hterapies 3)ECOG Performance Status:0-1 4)patient's agreement to this study 5)men aged 20 years and older

Exclusion criteria

Exclusion criteria: 1)patinets with another active cancers 2)patinets with severe cardiovascular diseases and diabetis militus 3)patients treated with 5a-reductase inhibitors for prostate hyperplasia 4)patientes treated with adrenocortical steroids 5)patinets with another anticancer agents 6)patients ineligible for this study judged by investigators

Design outcomes

Primary

Measure	Time frame
biochemical recurrence free survival	—

Secondary

Measure	Time frame
progression free survival, over all survival	—

Countries

Japan

Contacts

Public ContactYoshhide Kawasaki

Tohoku University Graduate School of Medicine Department of Urology

kawasaki@uro.med.tohoku.ac.jp022-717-7278

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026